Filters

Pp-125 manufacturers

Filters

None products found

pp-125

Concentrate for solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
MHRA
Comments
Indication: Locally advanced or metastatic urothelial carcinoma (Nectin-4-expressing), 2L+ after platinum and checkpoint inhibitor Clinical stage: Phase 2/3 Modality: Biologic (Bicycle-toxin conjugate; bicyclic peptide conjugated to MMAE) Mechanism / Target: Targets Nectin-4 on tumour cell surface via bicyclic peptide; delivers MMAE cytotoxin causing tubulin disruption and apoptosis Route / form: Intravenous infusion Differentiation: Smaller molecular size than ADCs enables better tumour penetration; no Fc-mediated off-target effects; faster renal clearance potentially reduces systemic toxicity
Manufacturer #39162

Clinical-stage biotech pioneering a novel class of bicyclic peptide-toxin conjugates for oncology. Focuses on targeted cancer therapy with differentiated pharmacological properties vs antibody-drug conjugates. Wholly owned pipeline pursuing global development.
Country: United Kingdom LinkedIn: https://www.linkedin.com/company/bicycle-therapeutics
GMP: Not disclosed

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.